Table 1. Phase 3 frontline studies with... | American Society of Hematology

Table 1.

Phase 3 frontline studies with doublet regimens in CLL

Agents	Study	Regimen	Patient population^a	PFS	uMRD rates	Median follow-up
BTKi & anti-CD20 antibody	A041202⁶^,⁷	IR	Median age: 71	Estimated 4-year: 76%	Marrow: 2%^b	55 months
	E1912⁵^,³²	IR	Mean age: 56.7	Estimated 5-year: 78%	NR	70 months
	iLLUMINATE⁸	IO	Median age: 70 Median CIRS score: 4	Estimated 30-month: 79%	Blood: 20%^c Marrow: 30%^c	31.3 months
	ELEVATE-TN⁹^,¹⁰^,³³	AO	Median age: 70 CIRS >6: 16.8%	Estimated 6-year: 78%	NR	74 months
Venetoclax & anti-CD20 antibody	CLL14¹⁵^,¹⁸	VO	Median age: 72 Median CIRS score: 8	Estimated 6-year: 53.1% Median: 76.2 months	Blood: 75.5%^d Marrow: 56.9%^d	76.4 months
	GIAIA/CLL13¹¹	VR	Median age: 62 Median CIRS score: 2	Estimated 4-year: 70.1%	Blood: 57.0%^e Marrow: 43.0%^f	50.7 months
	GIAIA/CLL13¹¹	VO	Median age: 62 Median CIRS score: 2	Estimated 4-year: 81.8%	Blood: 85.6%^e Marrow: 72.5^f	50.7 months
BTKi & venetoclax	GLOW³	IV	Median age: 71 Median CIRS score: 9	Estimated 2-year: 84.4%	Blood: 54.7%^d Marrow: 51.9%^d	27.2 months
BTKi & venetoclax	FLAIR²⁴	IV	Median age: 62	Estimated 3-year: 97.2%	Blood: 92.7%^g Marrow: 65.9%^g	43.7 months

Agents	Study	Regimen	Patient population^a	PFS	uMRD rates	Median follow-up
BTKi & anti-CD20 antibody	A041202⁶^,⁷	IR	Median age: 71	Estimated 4-year: 76%	Marrow: 2%^b	55 months
	E1912⁵^,³²	IR	Mean age: 56.7	Estimated 5-year: 78%	NR	70 months
	iLLUMINATE⁸	IO	Median age: 70 Median CIRS score: 4	Estimated 30-month: 79%	Blood: 20%^c Marrow: 30%^c	31.3 months
	ELEVATE-TN⁹^,¹⁰^,³³	AO	Median age: 70 CIRS >6: 16.8%	Estimated 6-year: 78%	NR	74 months
Venetoclax & anti-CD20 antibody	CLL14¹⁵^,¹⁸	VO	Median age: 72 Median CIRS score: 8	Estimated 6-year: 53.1% Median: 76.2 months	Blood: 75.5%^d Marrow: 56.9%^d	76.4 months
	GIAIA/CLL13¹¹	VR	Median age: 62 Median CIRS score: 2	Estimated 4-year: 70.1%	Blood: 57.0%^e Marrow: 43.0%^f	50.7 months
	GIAIA/CLL13¹¹	VO	Median age: 62 Median CIRS score: 2	Estimated 4-year: 81.8%	Blood: 85.6%^e Marrow: 72.5^f	50.7 months
BTKi & venetoclax	GLOW³	IV	Median age: 71 Median CIRS score: 9	Estimated 2-year: 84.4%	Blood: 54.7%^d Marrow: 51.9%^d	27.2 months
BTKi & venetoclax	FLAIR²⁴	IV	Median age: 62	Estimated 3-year: 97.2%	Blood: 92.7%^g Marrow: 65.9%^g	43.7 months

^aAge reported in years. ^bAfter 8 cycles of treatment. ^cCollected prior to subsequent treatment. ^dAssessed 3 months after treatment completion. ^eAt month 15 of treatment. ^fAt final restaging in patients with a compete remission. ^gAt 5 years of treatment.

Regimens: AO, acalabrutinib and obinutuzumab; BTKi, BTK inhibitor; IO, ibrutinib and obinutuzumab; IR, ibrutinib and rituximab; IV, ibrutinib and venetoclax; VO, venetoclax and obinutuzumab; VR, venetoclax and rituximab. CIRS, Cumulative Illness Rating Scale; NR, not reported; PFS, progression-free survival; uMRD, undetectable measurable residual disease.

[ViewLarge]

This Feature Is Available To Subscribers Only